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Abstract
Background: Although there are studies investigating the pathologic origins of mild cognitive impairment (MCI),
they have revolved around comparisons to normal elderly individuals or those with Alzheimer’s disease (AD) or
other dementias. There are few studies directly comparing the comprehensive neuropathology of amnestic (aMCI)
and nonamnestic (naMCI) MCI.
Methods: The database of the Brain and Body Donation Program (www.brainandbodydonationprogram.org), a
longitudinal clinicopathological study of normal aging and neurodegenerative disorders, was queried for subjects
who were carrying a diagnosis of aMCI or naMCI at the time of autopsy. Neuropathological lesions, including
neuritic plaques, neurofibrillary tangles (NFTs), Lewy bodies (LBs), infarcts, cerebral white matter rarefaction (CWMR),
cerebral amyloid angiopathy (CAA), and concurrent major clinicopathological diagnoses, including Parkinson’s
disease (PD) were analyzed.
Results: Thirty four subjects with aMCI and 15 naMCI met study criteria. Subjects with aMCI were older at death (88
vs. 83 years of age, p = 0.03). Individuals with naMCI had higher densities of LBs within the temporal lobe (p = 0.04)
while subjects with aMCI had a propensity for increased NFTs in parietal and temporal lobes (p values = 0.07). After
adjusting for age at death, the only significant difference was greater densities of temporal lobe NFTs within the
aMCI group. Other regional pathology scores for plaques, NFTs, and LBs were similar between groups. Subjects met
clinico-pathological criteria for co-existent PD in 24 % aMCI and 47 % naMCI while neuropathological criteria for AD
were met in equal percentages of aMCI and of naMCI cases (53 %); these proportional differences were not
significant (p values > 0.35). Furthermore, regardless of amnestic status, there was a greater presence of CAA (71 %
of MCI with executive dysfunction vs. 39 % without p = 0.03) and a greater presence of CWMR (81 % of MCI with
executive dysfunction and 54 % without p = 0.046) in MCI cases with executive dysfunction.
Conclusions: No single pathologic entity strongly dichotomized MCI groups, perhaps due to the pathologic
heterogeneity found within both entities. However, these data suggest the possibility for naMCI to have a
propensity for increased LBs and aMCI for increased NFTs in select anatomic regions.
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Background
Mild cognitive impairment (MCI) is a clinical diagnostic
term for elderly subjects with defined forms of cognitive
dysfunction that do not meet criteria for dementia [1]. In
most subjects, MCI is an intermediate phase between
normal cognition and dementia. The term was first used
nearly a quarter of a century ago by Reisberg and col-
leagues, who observed a progression to dementia in an
elderly population with mildly impaired cognitive function
[2]. Thirteen years later, the classification of MCI as pro-
posed by the 2nd International Working Group on MCI
Criteria included the subtypes of amnestic MCI (aMCI)
and nonamnestic MCI (naMCI) [1, 3]. Memory impair-
ment is the defining feature of aMCI, while naMCI is de-
fined by deficits of other cognitive abilities, including
attention, executive function, visuospatial skills, and lan-
guage. Both aMCI and naMCI may affect single or mul-
tiple neuropsychological domains. In 2011, criteria were
published focusing on MCI due to Alzheimer's disease
(AD) [4].
Most studies investigating the pathologic origins of MCI
have revolved around comparisons to normal elderly indi-
viduals or those with AD or other dementias [5–13].
There are few studies directly comparing the comprehen-
sive neuropathology of aMCI and naMCI. It is critical to
investigate pathological similarities and differences be-
tween aMCI and naMCI given the proposed dichotomous
progression of each of these diagnoses- i.e. aMCI progres-
sing more towards AD [9, 12]. The purpose of this study
is to compare and contrast common neuropathologies in
subjects who were diagnosed with aMCI or naMCI.
Methods
Subjects
Subjects were selected from the Arizona Study of Aging
and Neurodegenerative Disorders (AZSAND) with autop-
sies in the Brain and Body Donation Program (BBDP) at
Banner Sun Health Research Institute in Sun City,
Arizona (www.brainandbodydonationprogram.org) [14,
15]. All enrolled subjects or their legal representatives sign
a written informed consent approved by an Institutional
Review Board (Western Institutional Review Board,
Puyallup, WA) before the time of death allowing both clin-
ical assessments during life and several options for brain
and/or body organ donation after death. The Institutional
Review Board approval covers any studies conducted with
data and/or tissues from deceased BBDP subjects. Permis-
sion to access the research database with HIPPA compliant
de-identified information was granted by the director of
the BBDP. Access to the research database is open to in-
vestigators who are part of the Arizona Alzheimer’s Disease
Consortium, the Arizona Parkinson’s Disease Consortium,
as well as researchers who are registered on the BBDP
website (www.brainandbodydonationprogram.org) all of
which are approved to access the database under the
Institutional Review Board. Annual visits and exams
for cognition and movement disorders and criteria for
clinical diagnoses are previously described [14]. All assess-
ments were conducted in accordance with the Declaration
of Helsinki.
The BBDP database was queried for individuals who
were autopsied between January 1997 through July 2014,
had at least one formal, standardized BBDP neurological
evaluation during life, were carrying a diagnosis of aMCI
or naMCI according to published criteria [1, 4] at their
last visit prior to death, and had a completed neuropatho-
logical evaluation. Cases were excluded if they had a
diagnosis of dementia or had been thought to have cogni-
tive dysfunction that was secondary to a medical illness. If
an individual was not seen within 18 months before death,
a standardized telephone interview was conducted with a
knowledgeable contact, typically next of kin, to evaluate
for the presence of dementia or a movement disorder in
the final year of life. Additionally, at least two years of
private medical records were available for each subject
and these were reviewed to provide supplementary infor-
mation where necessary.
Clinical assessment
Prior to death, all participants were assessed annually on a
variety of clinical, neuropsychological, and functional
measures as described previously [14]. Cognition was
assessed using an array of measures, which are detailed in
a recent publication of the BBDP [15]. A supervising geri-
atric psychiatrist and neuropsychologist (SJ and CB, re-
spectively) at the Banner Sun Health Research Institute
oversaw administration of these measures. Results of these
assessments were jointly interpreted by a geriatric psych-
iatrist (SJ), behavioral neurologist (MNS, RJC), movement
disorders neurologist (CHA, HAS, JNC, ED), and neuro-
psychologist (CB) in order to reach a consensus diagnosis
for each individual. With respect to initial disagreements
among the consensus panel, all collateral information
available (previous years’ assessments, medical records,
non-cognitive questionnaires, mood measures, functional
assessments, etc.) is reviewed and discussed until a
consensus is reached. For the clinical diagnoses of aMCI
and naMCI, published criteria were used in which neuro-
psychological test performance fell at or below 1.5 stand-
ard deviations in one or more domains of cognition [1, 4].
Neuropathological assessment
All cases underwent autopsy and had a standardized neuro-
pathological assessment blinded to clinical categorization.
The final clinicopathological diagnoses were based on both
the neuropathology and clinical characteristics as obtained
from standardized neurological assessments as well as
review of private medical records. Criteria for these
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diagnoses have been reviewed elsewhere [16, 17]. A clinico-
pathological diagnosis of Parkinson's disease (PD) was
made if the subject had two or more cardinal clinical signs
(rest tremor, bradykinesia, rigidity) as well as Lewy bodies
and pigmented neuron loss in the substantia nigra. All sub-
jects were genotyped for apolipoprotein E (ApoE) using a
modification of a standard method [18].
Tissue processing methods have been previously de-
scribed [14, 19]. In brief, formaldehyde-fixed 5 μm
paraffin-embedded sections were stained with
hematoxylin and eosin, while large-format, 40–80 μm-
thick formaldehyde-fixed sections were stained for pla-
ques, tangles and other features using Gallyas, Thioflavin-
S and Campbell-Switzer methods [20]. All subjects were
classified according to the Unified Staging System for
Lewy Body (LB) Disorders [21] after immunohistochemi-
cal evaluation of phosphorylated α-synuclein on 5 μm
paraffin sections [22]. Individuals with incidental LBs
(iLBs) were defined as those lacking signs of parkinsonism
and/or dementia during life but with autopsy findings of
positive phosphorylated α-synuclein-immunoreactive
neuronal elements, morphologically consistent with Lewy-
type pathologies. Semi-quantitative analyses of neuritic
plaques (NP) and neurofibrillary tangle (NFT) densities
were done using standardized Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) published tem-
plates [23]; estimates of none, sparse, moderate, or fre-
quent were converted to a continuous 0-3 scale for
statistical purposes. Regions scored included cortical gray
matter from standard levels of frontal, parietal, and tem-
poral lobes, as well as hippocampal and entorhinal re-
gions. Global NP and NFT scores were obtained by
summation of all regions analyzed with a maximum score
of 15. For this study, subjects received a pathological diag-
nosis of AD if they were classified as “intermediate” or
“high” according to the NIA-Reagan criteria, regardless of
the absence of dementia [24]; Braak NFT stage was also
determined [25]. Cerebral white matter rarefaction
(CWMR) was defined as having 26 % or more of the cen-
trum semiovale affected in one or more of the following
lobes: frontal, parietal, occipital, and temporal; these
methods have been published previously [26]. Cerebral
amyloid angiopathy (CAA) was graded by density of amy-
loidotic blood vessels, using a 0–3 scale analogous to
CERAD templates [23]. Brain neoplasms were defined as
primary or metastatic parenchymal tumors and did not in-
clude meningiomas or schwannomas. Argyrophilic grains
(Arg) were defined as typical spindle-shaped structures re-
vealed by the Gallyas silver stain [27]. Presence/absence of
non-acute infarcts were categorized by affected region
(cortical, centrum semiovale, deep nuclei, and/or infraten-
torial regions) and by size (microscopic (not grossly vis-
ible), lacunar (<1 cc), small (1–27 cc), and large (>27 cc)).
Infarct groups were not mutually exclusive. For evaluation
of mixed pathologies- only the three diagnoses of 1) meet-
ing neuropatholgic criteria for AD; 2) cases having LBs in
areas other than the olfactory bulb, and 3) presence of
non-acute infarcts were considered. These were then
divided into cases with none, one, two, or three of the
mentioned diagnosis; similar methods have been done
previously [28].
Statistical analysis
Two-tailed, unpaired t tests were used to compare differ-
ences between aMCI and naMCI cases on age at death,
time from MCI diagnosis to death, years of education,
Mini Mental State Examination (MMSE) score and Part
III (motor) of the Unified Parkinson’s Disease Rating
Scale (UPDRS). Pearson chi-square tests were used to
determine differences in frequency for neuropathological
diagnosis of AD, concurrent major clinicopathological
diagnoses, Arg, CAA, CWMR, brain neoplasms, iLBs,
infarcts, gender, and ApoE ε4 carrier status. The Fisher
exact test was used instead of the Pearson chi-square
test when the minimum expected cell count was less
than five. The Wilcoxon rank-sum test was used to com-
pare Braak stage, NP score, and Unified Lewy Body
stage. After initial analyses, all data were then adjusted
for age at death.
Results
Overall demographics
Of the 1185 autopsied BBDP subjects queried, 49 (4 %)
met inclusion criteria for aMCI or naMCI. Of these 49
subjects, 20 (40 %) were female, mean (±SD) age at death
was 87 ± 7.8 years (range 69–103 years), and the aver-
age time from last neurological evaluation to death was
14 ± 13.3 months (range 2 to 65 months). Thirty-four
(69 %) met criteria for aMCI, while 15 (31 %) were naMCI.
Differences and similarities between aMCI and naMCI
Demographic and pathologic characteristics of the two
groups are displayed in Table 1. The aMCI group was sig-
nificantly older, but there were no large differences with
respect to gender ratios, ApoE4 carrier frequency (there
were no aMCI or naMCI that were homozygous for
ApoE4), time from last neurological (neuro) exam until
death, last MMSE score and last UPDRS score. With
respect to domains affected, naMCI has significantly
greater frequencies of cases with executive dysfunction
(67 vs. 32 %, p = 0.03). There were no other large differ-
ences with respect to demographic information between
aMCI and naMCI (differences less than 22 percentage
points or 0.4 standard deviations).
Some subjects had concomitant clinicopathological
diagnoses (Table 2), including Parkinson’s disease (PD),
progressive supranuclear palsy (PSP), motor neuron dis-
ease (MND), and multiple system atrophy (MSA);
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frequencies of these diagnoses were not substantially dif-
ferent between aMCI and naMCI (differences less than 22
percentage points). Subjects met clinicopathological cri-
teria for co-existent PD in 24 % aMCI and 47 % naMCI
while neuropathological criteria for AD were met in equal
percentages of aMCI and of naMCI cases (53 %).
All MCI cases had one or more of the following path-
ologies: neurofibrillary tangles (NFTs), NP, and LBs– the
most common being NFTs. All aMCI and naMCI con-
tained at least some NFTs, while 12 (35 %) aMCI and 6
(40 %) naMCI were devoid of NP in all areas examined;
categories of age related CERAD NP density scores and
Braak NFT staging are listed in Table 2. Both aMCI and
naMCI had similar distributions and densities of NP
(Table 3). However, for NFTs, there was a propensity for
aMCI to have higher densities than naMCI in the tem-
poral and parietal lobe (Bayes posterior probability 96 %),
although this did not reach statistical significance (P
values = 0.07). For the presence of Lewy-type alpha-
synucleinopathy (Table 3), only the temporal lobe was
statistically significant (p = 0.04) with naMCI having
greater densities than aMCI. With respect to overall
differences in LBs (i.e. examining just for the presence of
LBs irrespective of any parkinsonian features), there were
no large differences based on the presence of LBs, with
38 % of aMCI and 43 % of naMCI having LBs (95 % CI:
-0.36 to 0.26 p = 0.73). After adjusting for age at death, the
only large difference was greater temporal lobe NFTs
within the aMCI group (95 % CI: 0.00 to 0.69, p = 0.05).
As for other pathologies, the most common pathologies in
aMCI and naMCI were CWMR (65 % aMCI and 67 %
naMCI) and CAA (67 % aMCI and 47 % naMCI). There
were only 2 cases with brain neoplasms both of which had
aMCI. There were also similar frequencies with respect to
Arg (37 % aMCI, 27 % naMCI) and acute infarcts (18 %
aMCI, 13 % naMCI). Frequencies for non-acute infarcts
are located in Table 4. The frequency for non-acute
infarcts for aMCI was 53 and 40 % for naMCI. There were
no significant differences on any infarct measures (loca-
tion and/or size) between aMCI and naMCI. No case had
a pathological diagnosis of hippocampal sclerosis.
With respect to mixed pathologies (infarcts, any LBs,
and/or a neuropathologic diagnosis of AD), 20 % of
naMCI and 5.9 % of aMCI contained none of the path-
ologies (p = 0.16, Fisher’s Exact Test), 33.3 % of naMCI
and 41.2 % of aMCI contained 1 of the pathologies (χ2 =
0.04 p = 0.84), 33.3 % of naMCI and 52.9 % of aMCI
contained at 2 of the pathologies (χ2 = 0.92 p = 0.34), and
13 % of naMCI contained all three (p = 0.09, Fisher’s
Exact Test) (Fig. 1).
Lastly, with respect to the presence/absence of executive
dysfunction (regardless of aMCI or naMCI status) there
were some significant differences. There was a significant
relationship between the presence of CAA and executive
dysfunction, (71 % of MCI with executive dysfunction and
39 % without executive dysfunction- 95 % CI: 0.06 to 0.59
p = 0.03) and also a significant relationship between the
presence of CMWR and executive dysfunction (81 % of
MCI with executive dysfunction and 54 % without - 95 %
CI: 0.02 to 0.52 p = 0.046).
Discussion
The current study demonstrates the vast array of neuro-
pathologic heterogeneity within MCI, suggesting that
Table 1 Demographic information of aMCI and naMCI cases in the BBDP. Mean ± SD or n (%)
aMCI (N = 34) naMCI (n = 15) 95 % CI P value
Female (%) 12 (35 %) 7 (47 %) −0.41 to 0.19 0.53
Multi-domain N (%) 13 (38 %) 4 (27 %) −0.16 to 0.39 0.43
Domains affected
Memory 34 (100 %) n/a n/a n/a
Executive 11 (32 %) 10 (67 %) −0.63 to −0.06 0.03
Language 4 (12 %) 5 (33 %) −0.50 to 0.03 0.11
Visuospatial 2 (6 %) 3 (20 %) −0.42 to 0.06 0.16
Attention 1 (3 %) 2 (13 %) −0.36 to 0.07 0.22
Age at death, yrs 88 ± 8 83 ± 7 0.4 to 9.8 0.03
Interval last neuro exam till death, months 15 ± 15 11 ± 7.7 −0.61 to 0.67 0.86
Education, yrs. 15 ± 3 16 ± 2 −3.3 to 0.0 0.05
APOE 4 carriers 9 (26 %) 6 (40 %) −0.43 to 0.15 0.50
Last MMSE 27 ± 2 27 ± 2 [n = 14] −1.8 to 0.9 0.55
Interval last MMSE till death, months 15 ± 15 10 ± 5 [n = 14] −3.3 to 13.2 0.23
Last UPDRS 20 ± 16 [n = 33] 23 ± 17 −13 to 8 0.63
Interval last UPDRS till death, months 15 ± 15 17 ± 19 −12 to 9 0.78
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there may be no single underlying etiology dichotomiz-
ing aMCI from naMCI. This is supported by previous
studies demonstrating multiple pathologies are found to
be present in MCI [5, 6, 10, 29]. This study differs from
most previous studies by directly comparing neuropath-
ology in two main subtypes of MCI, i.e. aMCI and
naMCI. Despite heterogeneity, MCI subtypes did have
propensities for certain demographic and pathological
measures. Individuals who came to autopsy with a diag-
nosis of aMCI during life were older at death, and were
less likely to have executive dysfunction when compared
to naMCI. Furthermore, amongst the plethora of path-
ologies, naMCI had a propensity for increased LBs and
aMCI increased NFTs in select anatomic regions.
Although there have been an increased number of stud-
ies investigating the pathologic origins of MCI, these have
mostly revolved around comparisons to cognitively nor-
mal elderly or those with AD or other dementias [5–13]
with few studies directly comparing neuropathological
differences between aMCI and naMCI. One of the best
studies on this comparison was conducted through the
Religious Orders Study/Rush Memory and Aging Project
(ROS/MAP) which examined LBs, and AD pathologies in
75 individuals who died with aMCI and 59 with naMCI
[10]. Although the ROS/MAP study did not describe
Table 2 Frequencies of pathologies within aMCI (N = 34) and
naMCI (N = 15) cases. All pathology groups are not mutually
exclusive; there is considerable overlap with concomitant
pathologies
aMCI naMCI p value
Clinicopathologic diagnoses
PD 8 (24 %)a 7 (47 %) 0.18
PSP 3 (9 %)a 3 (20 %) 0.35
MND 0 1 (7 %) 0.31
MSA 1 (3 %) 0 1.00
Other pathologies
Met neuropath criteria for AD 18 (53 %) 8 (53 %) 1.00
Braak NFT stage 0.22
I 2 (6 %) 0
II 2 (6 %) 2 (13 %)
III 3 (9 %) 5 (33 %)
IV 23 (68 %) 8 (53 %)
V 3 (9 %) 0
VI 1 (3 %) 0
CERAD NP score 0.90
None 12 (35 %) 6 (40 %)
Sparse 2 (6 %) 1 (7 %)
Moderate 8 (24 %) 2 (13 %)
Frequent 12 (35 %) 6 (40 %)
Incidental LBs 5 (15 %) 0 0.31
Unified LB staging scheme 0.18
Stage 0. no LBs 21 (62 %) 8 (53 %)
Stage 1. OBT only 2 (6 %) 0
Stage IIa. Brainstem 3 (9 %) 1 (7 %)
Stage IIb. Limbic 3 (9 %) 0
Stage III. Limbic + Brainstem 3 (9 %) 3 (20 %)
Stage IV. Neocortical 2 (6 %) 3 (20 %)
aOne aMCI case had both PSP and PD; there were no other overlapping
clinicopathological diagnoses
Table 3 Semi-quantitative analyses of neuritic plaques (NP) and
neurofibrillary tangles (NFT), Lewy-type synucleinopathy (listed
as average (mean)), and other pathologies (listed as frequencies)
within aMCI (N = 34) and naMCI (N = 15)
aMCI naMCI 95 % CI p-value
Neuritic plaques
Frontal lobe 1.5 (1.3) 1.8 (1.3) −1.0 to 0.6 0.55
Temporal lobe 1.5 (1.3) 1.5 (1.3) −0.7 to 0.9 0.88
Parietal lobe 1.6 (1.3) 1.7 (1.7) −1.0 to 0.7 0.76
Hippocampus region 0.7 (0.9) 0.7 (0.8) −0.53 to 0.53 1.00
Entorhinal region 1.3 (1.3) 1.3 (1.0) −0.8 to 0.8 0.97
Total
(all areas; score out of 15)
6.6 (5.7) 1.2 (5.2) −4.3 to 2.9 0.11
Neurofibrillary tangles
Braak NFT stage IV (I-VI) III (II-IV) −0.22 to 0.95 0.22
Frontal lobe 0.4 (0.6) 0.2 (0.3) −0.06 to 0.60 0.11
Temporal lobe 1 (0.8) 0.6 (0.7) −0.04 to 0.91 0.07
Parietal lobe 0.4 (0.6) 0.1 (0.2) −0.02 to 0.60 0.07
Hippocampus region 2.2 (0.9) 2.0 (0.9) −0.30 to 0.80 0.36
Entorhinal region 2.6 (0.8) 2.5 (0.8) −0.38 to 0.60 0.66
Total
(all areas; score out of 15)
6.6 (2.8) 5.2 (2.3) −0.3 to3.1 0.11
Lewy type synucleinopathy
Olfactory bulb 1.1 (1.6) 1.5 (1.8) −1.5 to 0.7 0.44
Cingulate cortex 0.6 (1.1) 1.2 (1.6) −1.4 to 0.1 0.11
Frontal lobe 0.2 (0.5) 0.4 (0.8) −0.55 to 0.22 0.39
Temporal lobe 0.2 (0.5) 0.7 (1.0) −0.9 to -0.3 0.04
Parietal lobe 0.2 (0.5) 0.5 (0.7) −0.64 to 0.12 0.17
Amygdala 0.9 (1.5) 1.5 (1.8) −1.5 to 0.5 0.29
Transentorhinal cortex 0.6 (1.1) 1.1 (1.5) −1.3 to 0.3 0.23
Total
(all areas; score out of 15)
6.6 (2.8) 5.2 (2.3) −0.3 to3.1 0.11
Other pathologies
Arg 13 (37 %) 4 (27 %) n/a 0.74
CWMR 22 (65 %) 10 (67 %) n/a 0.89
CAA 16 (47 %) 10 (67 %) n/a 0.21
Brain neoplasms 2 (6 %) 0 n/a 1.0
Acute infarcts 6 (18 %) 2 (13 %) n/a 1.0
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anatomic distributions of LBs, AD pathologies, CAA,
CWMR, or Arg, they did demonstrate that 59 % of aMCI
met pathological criteria for the diagnosis of AD com-
pared to 49 % of naMCI; these percentages are very simi-
lar to those presented in the current study. The ROS/
MAP study also had similar conclusion that many individ-
uals with MCI exhibit mixed pathologies, thus emphasiz-
ing pathological heterogeneity.
In this cross-sectional study, although no global differ-
ences in AD pathology were found (i.e. meeting patho-
logical criteria for AD), certain anatomic regions (parietal
and temporal lobes) had a propensity for increased NFTs
in subjects with aMCI (p values = 0.07). Furthermore, in
both MCI groups, no cases were completely devoid of
NFTs. In contrast, 26/50 (52 %) of MCI cases were devoid
of NPs. Given temporal lobe structures are affected early
within the pathologic course of AD (as determined by
Braak NFT stages) [25], this is in support of clinical studies
having shown aMCI to have a greater conversion rate to
probable AD than naMCI [29, 30]. When examining MCI
as one entity, several studies have described the presence
of increased numbers of NFTs in subjects with MCI as
compared with similarly-aged normal subjects, especially
in medial temporal lobe structures [30, 31]. Others have
examined similarities in pathology between aMCI and
AD, suggesting that aMCI is identical to early AD based
on NFT distribution [7, 9].
As for other neuropathological comparisons, a recent
pathologic study demonstrated naMCI to have a greater
conversion rate to dementia with LBs by time of autopsy
[12]. With respect to PD, in a multicenter, pooled, clinic-
ally based study examining 347 PD with MCI, 49 % had
naMCI and 51 % had aMCI [32]. Other data from the
BBDP published on MCI within the setting of PD, too
small to correlate pathologic and clinical findings, revealed
varying LBs distribution [29]. In the current study, there
was no large difference in the concurrency rate of clinico-
pathologically defined PD; however, Lewy-type alpha-
Table 4 Infarcts (excluding acute) in aMCI and naMCI organized by location and size (microscopic (not grossly visible), lacunar
(<1 cc), small (1-27 cc), and large (>27 cc)). All data listed as N (%). Groups are not mutually exclusive
aMCI
Area affected Total cases Microscopic Lacunar Small Large
Cortical 10 (29 %) 8 (24 %) 2 (6 %) 2 (6 %) 2 (6 %)
Centrum semiovale 3 (9 %) 2 (6 %) 1 (3 %) 1 (3 %) 1 (3 %)
Deep nuclei 12 (35 %) 4 (12 %) 9 (26 %) 2 (6 %) 1 (3 %)
Infratentorial 14 (41 %) 12 (35 %) 2 (6 %) 2 (6 %) 1 (3 %)
naMCI
Area affected Total cases Microscopic Lacunar Small Large
Cortical 3 (20 %) 1 (7 %) 0 2 (13 %) 1 (7 %)
Centrum semiovale 3 (20 %) 0 2 (13 %) 0 1 (7 %)
Deep nuclei 3 (20 %) 2 (13 %) 2 (13 %) 0 0
Infratentorial 3 (20 %) 2 (13 %) 1 (7 %) 0 0
Fig. 1 Pie charts depicting the frequencies of the number of mixed pathological diagnoses (infarcts, LBs, and neuropathological diagnosis of AD)
for aMCI and naMCI
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synucleinopathy had greater densities in the temporal lobe
of naMCI. This distinct anatomic difference may be due
to the temporal lobe (similar to data on NFTs) being
affected somewhat early in the Lewy-type alpha-synuclein
disease process [21].
Other pathologies, outside the realm of major
clinicopathologically-defined conditions, such as CWMR,
Arg, and CAA, may exist within MCI as well as within
clinically normal elderly individuals. The most common
pathology within the aMCI and naMCI groups were
CWMR and CAA and both were equally common,
although reports have demonstrated that CWMR and
CAA have a greater association with AD [33–36]. Al-
though no large associations were found with respect to
amnestic type, there were associations with the executive
dysfunction. Cases with executive dysfunction had larger
frequencies of CWMR and CAA. A radiological study of
white matter lesions in 129 patients demonstrated that the
severity of white matter lesions was not associated with
time to conversion to dementia for either MCI patients in
general or amnestic MCI patients in particular [37]. Our
frequencies of Arg in each subgroup are very similar to
those that have been previously reported for the entire
MCI entity [5].
One of the difficulties in conducting pathologic studies
on MCI patients after death is that few autopsies have
been done on individuals who died while still in the MCI
stage; this is evident in the current study with less than
5 % of the total number of BBDP participants having died
in the MCI stage. Larger samples would be needed in
order to detect or rule out smaller subtle differences
between aMCI and naMCI. This study further emphasizes
the dire need for in-vivo biomarkers that could demon-
strate disease progression of LBs and NFTs, thus providing
firmer conclusions. Individuals who die and undergo aut-
opsy while in the MCI state may not represent the full
spectrum of MCI due to survival bias, reversion back to
normal cognition, and those who converted to dementia
before death. One report revealed the mean time to devel-
oping dementia from MCI baseline was 3.1 years for those
eventually diagnosed as clinically probable AD, while this
was 2.6 years for those eventually diagnosed with demen-
tia with Lewy bodies [12]. Furthermore, cases included in
this study were mainly elderly volunteers, typically over
the age of 70 at enrollment. Due to the emphasis of the
program being the study of normal aging, PD, as well as
dementia there is a recruitment bias towards enrolling
subjects in these categories. Hence there may be an over-
representation of Parkinsonian diagnoses in aMCI and
naMCI- although no differences were seen between
groups. Although this study had limitations, such as the
small sample size and the greater proportion of aMCI
cases, perhaps due to the known prevalence of MCI sub-
types [6, 38], it is the most comprehensive study to date
analyzing a full range of pathologies among amnestic and
nonamnestic MCI subjects.
Conclusions
This small study suggests there may be no single under-
lying entity strongly associated with a specific domain
deficit within MCI, given the finding of multiple patholo-
gies within aMCI and naMCI. Although there is a plethora
of pathologies, naMCI had a propensity for an increased
density of LBs and aMCI for increased NFTs in select ana-
tomic regions. Furthermore, executive dysfunction in the
setting of MCI was associated with the presence of
CWMR and CAA.
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